53 results about "Pravastatin Sodium" patented technology

The invention discloses a liposome preparation of sodium aspirin and sodium pravastatin. The liposome is mainly prepared from the following components in part by weight: 20 to 40 parts of sodium aspirin, 81 parts of sodium pravastatin, 200 to 1,000 parts of hydrogenated soybean phosphatidylcholine, 50 to 500 parts of cholesterol and 100 to 400 parts of poloxamer 188. The invention also discloses a solid preparation of a sodium aspirin and sodium pravastatin medicinal composition, which is prepared from the liposome preparation of sodium aspirin and sodium pravastatin, and other excipients usually used pharmaceutically. The quality of the preparation is improved and the toxic and side effects are reduced.

The present relates to a pravastatin preparation formula for curing angiocardiopathy. It is characterized by that said formula contains medicinal active component pravastatin sodium, at the same time contains one or several kinds of amino acids or amino acid salts as stabilizing agent, and the pH value of pravastatin preparation aqueous emulsion is 6.0-8.9.

A process for purifying pravastiation sodium includes such steps as making the fermented liquid containing pravastatin sodium in contact with adsorptive resin, separating them from each other, washing the adsorptive resin with water, C1-4 alcohol, C1-4 ketone, or their mixture, making the eluted liquid in contact with the washed adsorptive resin, and collecting the eluted liquid containing the purified pravastation sodium. Its advantages are high purity of product and less environmental pollution.

The invention provides a novel microorganism Pseudonocardia sp. RMRC PAH4 characterized in that it is able to degrade high concentration of quinoline by enrichment culture, shows a high tolerance to compactin-sodium and possesses a high hydroxylation activity of converting compactin-sodium to pravastatin-sodium. The invention relates also a process for converting compactin-sodium into pravastatin-sodium by fermenting said novel microorganism Pseudonocardia sp. RMRC PAH4. Pravastain-sodium is a potent cholesterol-lowering agent used in treatment for hypercholesterolemia.

The invention provides a freeze-dried powder of a pravastatin sodium composition for injection, and relates to the technical field of medicines and medicine production. The freeze-dried powder comprises the following raw materials by weight: 1 part of pravastatin sodium, 0.2-1.4 parts of chitosan nanoparticles and 100-200 parts of water for injection. The freeze-dried powder has the advantages that (1) chitosan, as a cosolvent, can increase solubility of pravastatin sodium in water and shorten dissolution time, and is helpful for clinical application; (2) the composition can significantly enhance a lipid-decreasing of pravastatin sodium, reduce usage amount of pravastatin sodium clinically and alleviate adverse effects of pravastatin sodium; in-vitro experiments demonstrate that the lipid-decreasing capacity of 10 mg of the freeze-dried powder of pravastatin sodium composition comprising the chitosan nanoparticles is equivalent to that of 20 mg of pravastatin sodium with no chitosan nanoparticles; and (3) chitosan nanoparticles can replace mannitol to be used as a freeze-drying skeleton agent, so that active effects of mannitol to a human body can be eliminated.

The invention provides a pravastatin sodium compound and a novel preparation method thereof. The method comprises the following steps of: (1) performing absorption and ion exchange on pravastatin sodium by using strongly acidic ion exchange resin; (2) eluting by using sodium carbonate or sodium bicarbonate aqueous solution at the concentration of 0.1 to 2 percent; and (3) separating and purifying the elution mother liquor by using a chromatographic column, collecting the eluted solution, washing by using water, drying by using a solid drying agent, concentrating under reduced pressure, evaporating to remove the eluted solution and obtaining a pravastatin sodium pure product. According to the high-purity pravastatin sodium compound prepared by the refining method, the purity and the content of the pravastatin sodium are increased greatly, the product quality of the preparation is improved, the toxic and side effects are reduced and the clinic medication safety is ensured; the method is simple in technology, low in cost and high in yield rate and is suitable for industrial production.

The invention provides a method for extracting and purifying pravastatin sodium from a fermentation liquor, and belongs to the field of biological medicine preparation. According to the method for extracting and purifying pravastatin sodium from the fermentation liquor, a large amount of impurities and pigments are removed by alkalizing and acidifying the fermentation liquor, and the effective components in an acidizing liquid are enriched by an adsorbent, so that the purity of an extraction substrate is improved, the quantity of the extraction substrate is greatly reduced, and the quality ofan extraction liquid is further improved; in the whole production process, a single solvent system is adopted, the process is not complicated, the generated three wastes are low in amount, and the method is suitable for large-scale production. The content of pravastatin sodium produced by the method is more than 98.8 percent, the content of main impurity 6-epipravastatin is less than 0.15%, the content of total related substances is less than 0.4%, the product quality accords with the EP9.6 edition quality standard (the content of the pravastatin sodium is between 97.0% and 102.0%; a main impurity A, namely6-epipravastatin, is less than or equal to 0.3%; the content of the total related substances is less than or equal to 0.6%) of qualified pravastatin sodium, the total yield can reach more than 75%, and the large-scale production prospect is good.

The invention relates to a composition containing statins and application thereof. The active ingredient of the composition is composed of statins and rimonabant, wherein the statins comprise atorvastatin calcium, simvastatin, pravastatin sodium and rosuvastatin calcium. The pharmaceutical composition provided by the invention can effectively prevent or treat fatty liver.

The invention discloses a pravastatin sodium liposome preparation. The pravastatin sodium liposome is mainly prepared from 1 weight part of pravastatin sodium, 3 to 10 weight parts of glycerol monoacetate, 1.5 to 6 weight parts of poloxamer 188 and 0.05 to 5 weight parts of sodium deoxycholate. The invention further discloses a pravastatin sodium liposome solid preparation. The solid preparation is prepared from the pravastatin sodium liposome preparation and other pharmaceutically common excipients. The product quality of the preparation is improved and the toxic or side effects are reduced.

A method of isolating or purifying pravastatin or its pharmaceutically acceptable salt characterized by involving, in the process of isolating or purifying pravastatin or its pharmacologically acceptable salt, the step of extracting pravastatin using an organic solvent represented by the formula CH3CO2R (wherein R represents an alkyl group having 3 or more carbon atoms) or the step of decomposing impurities using an inorganic acid or an inorganic base; and compositions containing pravastatin sodium thus obtained.

The invention belongs to the field of pharmaceutical preparations and in particular relates to pravastatin sodium dispersible tablets and a preparation method thereof. Because the oral absorption bioavailability of pravastatin sodium is low, and the difference between medication individuals is large, the invention provides pravastatin sodium dispersible tablets. The pravastatin sodium dispersible tablets contain pravastatin sodium, hydroxypropyl-beta-cyclodextrin, filler, a disintegrating agent, an adhesive and a lubricating agent. The pravastatin sodium easily dissolves in water after being subjected to inclusion of hydroxypropyl-beta-cyclodextrin (HP-beta-CD), the stability of the medicine is improved, release of the medicine in vivo is promoted, the absorption is improved, the bioavailability is improved, and the difference between medication individuals is reduced.

A dripping pill of pravastatin sodium for treating hyperlipemia is prepared from the pravastatin sodium and the matrix of dripping pill. Its preparing process is also disclosed.

The invention relates to an oral drug preparation containing pravastatin, in particular to an oral solid formulation with reinforced effect of pravastatin, which comprises effective amount of pravastatin and pharmaceutical adjuvant, wherein the pharmaceutical adjuvant comprises an enwrap agent; the weight proportion of the pravastatin and the wrapping agent ranges from 1: 0.2 to 1: 10. The oral drug has the advantages of quick effects, reinforced active components and easy administration without uncomfortable feeling.

The present invention provides pravastatin sodium substantially free of pravastatin lactone and epiprava, the C-6 epimer of pravastatin. The present invention further provides a novel process for recovering pravastatin sodium from a fermentation broth in such high purity. The process includes the stages of forming an solution of the compound by extraction, obtaining an ammonium salt of pravastatin from the solution, purifying the ammonium salt of the compound and transposing the salt of the compound to pravastatin sodium.

The present invention relates to a crystal form of Pravastatin Na, and a preparation method and application thereof. The crystal form is named as a U crystal form. In an X-ray powder diffraction pattern, diffraction angle of 20 degrees, infrared spectrum and endothermic peak in the curve characteristic of a differential scanning calorimeter are defined. The Pravastatin Na in any forms is dissolvedin an acid amide solvent to form a solution, the temperature is preferably 30 to 90 DEG C, and the mass ratio of the acid amide solvent to the Pravastatin Na is preferably 3 to 7:1; a dissolving agent is added in the Pravastatin Na solution, the mass of the dissolving agent is 3 to 15 times of that of the solvent, and then a suspension is formed; the suspension is separated and dried, and the U crystal form of the Pravastatin Na is obtained. Through the XRD pattern and the photographs of a scanning electron microscope, it is confirmed that the product has the advantages of high crystallinity,large crystal size, smooth crystal surface and high filtering speed, and the filtering time of crystal mush with the same density and same volume can be saved by more than one half. The U-form Pravastatin Na crystal as a medicine composite has the purpose of treating atherosclerosis or hypercholesterolemia.

The invention provides a preparation method of a compound composition containing active ingredients fenofibrate and pravastatin sodium. The preparation method is characterized in that the pravastatin sodium exists in the composition in the form of quick-release pellets; the fenofibrate exists in the composition in the form of solid dispersoid or semi-solid particles. The preparation method of the composition aims to solve the problem about the bioavailability of the fenofibrate and the pravastatin sodium with completely different solubility and the problem about the stability when the fenofibrate and the pravastatin exist in the same component commonly.